程序性细胞死亡蛋白1/程序性细胞死亡配体1抑制剂在晚期三阴性乳腺癌中的现状
Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer.
作者信息
Liang Yuehua, Liu Xiaoran, Li Kun, Li Huiping
机构信息
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
出版信息
Chin J Cancer Res. 2022 Apr 30;34(2):117-130. doi: 10.21147/j.issn.1000-9604.2022.02.07.
Abstract
Triple-negative breast cancer (TNBC) has the worst prognosis among all molecular types of breast cancer. Because of the strong immunogenicity of TNBC cells, programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors, two kinds of immune checkpoint blockade agents, might help improve the prognosis of TNBC. However, how to better use PD-1/PD-L1 inhibitors and select patients who may benefit from treatment options remains controversial. This article summarizes published clinical studies in which PD-1/PD-L1 inhibitors were used in patients with advanced TNBC to explore how to maximize effectiveness of these medications.
摘要
三阴性乳腺癌（TNBC）在所有分子类型的乳腺癌中预后最差。由于TNBC细胞具有较强的免疫原性，程序性死亡1/程序性死亡配体1（PD-1/PD-L1）抑制剂这两种免疫检查点阻断剂可能有助于改善TNBC的预后。然而，如何更好地使用PD-1/PD-L1抑制剂以及选择可能从治疗方案中获益的患者仍存在争议。本文总结了已发表的关于在晚期TNBC患者中使用PD-1/PD-L1抑制剂的临床研究，以探讨如何使这些药物的疗效最大化。
相似文献
1
Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer.程序性细胞死亡蛋白1/程序性细胞死亡配体1抑制剂在晚期三阴性乳腺癌中的现状
Chin J Cancer Res. 2022 Apr 30;34(2):117-130. doi: 10.21147/j.issn.1000-9604.2022.02.07.
2
Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review.程序性细胞死亡蛋白1/程序性细胞死亡配体1抑制剂治疗三阴性乳腺癌的疗效和安全性概况：一项全面的系统评价
Oncol Rev. 2019 Oct 10;13(2):425. doi: 10.4081/oncol.2019.425. eCollection 2019 Jul 22.
3
A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.PD-L1 抑制性 microRNAs 治疗三阴性乳腺癌的系统评价：迈向单细胞测序指导的仿生递药。
Genes (Basel). 2021 Aug 4;12(8):1206. doi: 10.3390/genes12081206.
4
Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.免疫检查点抑制剂在三阴性乳腺癌（TNBC）中的应用：前路在何方。
Cancer. 2018 May 15;124(10):2086-2103. doi: 10.1002/cncr.31272. Epub 2018 Feb 9.
5
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).免疫检查点抑制剂的治疗候选物由三阴性乳腺癌（TNBC）中肿瘤浸润淋巴细胞（TILs）和程序性死亡配体 1（PD-L1）表达的状态所阐明。
Breast Cancer. 2018 Jan;25(1):34-42. doi: 10.1007/s12282-017-0781-0. Epub 2017 May 9.
6
Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer.克服三阴性乳腺癌中PD-1/PD-L1阻断抗性的机制与策略
Cancers (Basel). 2022 Dec 23;15(1):104. doi: 10.3390/cancers15010104.
7
Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.2-脱氧葡萄糖对PD-L1的去糖基化作用可逆转PARP抑制剂诱导的三阴性乳腺癌免疫抑制。
Am J Cancer Res. 2018 Sep 1;8(9):1837-1846. eCollection 2018.
8
The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer.抗血管生成药物与PD-L1抑制剂联合作用对三阴性乳腺癌细胞凋亡的影响及机制
Ann Transl Med. 2023 Jan 31;11(2):83. doi: 10.21037/atm-22-6446.
9
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.早期三阴性乳腺癌中靶向PD-1/PD-L1的免疫疗法
J Pers Med. 2023 Mar 15;13(3):526. doi: 10.3390/jpm13030526.
10
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.程序性死亡配体1（PD-L1）肿瘤表达与三阴性乳腺癌患者的较好预后及糖尿病疾病相关。
Int J Mol Sci. 2017 Feb 21;18(2):459. doi: 10.3390/ijms18020459.
引用本文的文献
1
Overview on Current Trends and Emerging Therapies in the Chemotherapy of Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.人表皮生长因子受体2阳性乳腺癌患者化疗的当前趋势与新兴疗法概述
Galen Med J. 2023 Aug 20;12:e3021. doi: 10.31661/gmj.v12i0.3021. eCollection 2023.
2
Manufacturing CAR-NK against tumors: Who is the ideal supplier?制造用于对抗肿瘤的嵌合抗原受体自然杀伤细胞（CAR-NK）：谁是理想的供应商？
Chin J Cancer Res. 2024 Feb 29;36(1):1-16. doi: 10.21147/j.issn.1000-9604.2024.01.01.
3
Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients.内分泌治疗联合HER2靶向治疗，是HR+/HER2+晚期乳腺癌患者的另一个理想选择。
Ther Adv Med Oncol. 2024 Jan 6;16:17588359231220501. doi: 10.1177/17588359231220501. eCollection 2024.
4
Predictive value of co-expression patterns of immune checkpoint molecules for clinical outcomes of hematological malignancies.免疫检查点分子共表达模式对血液系统恶性肿瘤临床结局的预测价值。
Chin J Cancer Res. 2023 Jun 30;35(3):245-251. doi: 10.21147/j.issn.1000-9604.2023.03.04.
5
Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors.微生物菌群对免疫检查点抑制剂治疗胃肠道肿瘤的影响。
Chin J Cancer Res. 2023 Jun 30;35(3):252-265. doi: 10.21147/j.issn.1000-9604.2023.03.05.
6
Apolipoprotein C1 promotes tumor progression in gastric cancer.载脂蛋白 C1 促进胃癌肿瘤进展。
Oncol Res. 2023 May 24;31(3):287-297. doi: 10.32604/or.2023.028124. eCollection 2023.
本文引用的文献
1
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.联合血管生成和 PD-1 抑制治疗免疫调节性三阴性乳腺癌：FUTURE-C-Plus 试验的概念探索和生物标志物分析。
Mol Cancer. 2022 Mar 25;21(1):84. doi: 10.1186/s12943-022-01536-6.
2
De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.肿瘤组织中去糖基化膜性程序性死亡配体1作为晚期乳腺癌患者对阿替利珠单抗（泰圣奇）反应性的生物标志物
Am J Cancer Res. 2022 Jan 15;12(1):123-137. eCollection 2022.
3
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.一项针对 IDO/PD-L1 免疫调节疫苗联合纳武利尤单抗治疗转移性黑色素瘤的 1/2 期临床试验。
Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9.
4
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).多中心二期临床试验：依匹单抗联合纳武利尤单抗治疗不可切除或转移性间变性乳腺癌：双重抗 CTLA-4 和抗 PD-1 阻断在罕见肿瘤中的队列 36（DART，SWOG S1609）。
Clin Cancer Res. 2022 Jan 15;28(2):271-278. doi: 10.1158/1078-0432.CCR-21-2182. Epub 2021 Oct 29.
5
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer.单细胞分析揭示了与三阴性乳腺癌对 PD-L1 阻断反应相关的关键免疫细胞亚群。
Cancer Cell. 2021 Dec 13;39(12):1578-1593.e8. doi: 10.1016/j.ccell.2021.09.010. Epub 2021 Oct 14.
6
Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer.每周紫杉醇与度伐利尤单抗联合应用于三阴性转移性乳腺癌，具有良好的安全性。
Sci Rep. 2021 Sep 27;11(1):19154. doi: 10.1038/s41598-021-98113-6.
7
Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.三阴性乳腺癌中 PDCD1（PD-1）、PD-L1（CD274）和 PD-L2（PDCD1LG2）DNA 甲基化的分子和免疫相关性。
J Immunother. 2021 Oct 1;44(8):319-324. doi: 10.1097/CJI.0000000000000384.
8
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.一线阿替利珠单抗联合白蛋白紫杉醇治疗不可切除、局部晚期或转移性三阴性乳腺癌：IMpassion130 最终总生存分析。
Ann Oncol. 2021 Aug;32(8):983-993. doi: 10.1016/j.annonc.2021.05.355. Epub 2021 Jul 1.
9
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.IMpassion131 研究是一项双盲、安慰剂对照、随机 III 期临床试验，旨在评估一线紫杉醇联合或不联合阿替利珠单抗治疗不可切除局部晚期/转移性三阴性乳腺癌的主要结果。
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.
10
potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors.增强同源重组缺陷肿瘤中的免疫检查点阻断疗法。
Theranostics. 2021 May 24;11(15):7175-7187. doi: 10.7150/thno.59056. eCollection 2021.
Zotero 插件